Project Grant R21CA304619
Award Date 9/1/26
Completion Date 8/31/28
Dollars Obligated $421K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Charlestown, MA 02129, USA
Similar Awards
- The National Cancer Institute, part of the Department of Health and Human Services, awarded $424,256 to The General Hospital Corporation (Massachusetts General Hospital, Research Management Division) on September 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop a computational framework for optimal immune monitoring during cancer treatment. The project constructs compartmental models connecting tissue-level lymphocyte dynamics to blood count data,...
- The National Cancer Institute awarded Massachusetts General Hospital $652,908 on September 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to support research restoring dendritic-cell-derived immune signaling to reinvigorate T cells in glioblastoma. The project addresses the failure of immunotherapy to produce durable benefit in glioblastoma multiforme, the most aggressive primary brain tumor in adults, where standard treatments—surgery, radiation, and temozolomide—extend...
- The National Cancer Institute awarded The General Hospital Corporation (Massachusetts General Hospital) $162,608 under the Cancer Treatment Research program (CFDA 93.395) on August 14, 2026. The award funds an exploratory research project characterizing how moderate-dose external radiotherapy enhances blood perfusion in hepatocellular carcinoma tumors, with the goal of optimizing combination strategies between ionizing radiation and perfusion-driven therapies. The research involves irradiating a...
- The National Institutes of Health National Cancer Institute awarded $421,825 to The General Hospital Corporation (Massachusetts General Hospital) on September 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop an improved fibrin-targeted radiopharmaceutical for gastric cancer treatment. The project addresses advanced gastric cancer, for which chemotherapy remains the standard treatment but nearly all patients eventually relapse or experience disease progression. The...
- The National Institutes of Health National Cancer Institute awarded Massachusetts General Hospital (The General Hospital Corporation) $707,798 on April 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to determine mechanisms of heterogeneous treatment response in glioblastoma using multi-omic and multi-organ approaches. The research identifies transcriptional, genetic, neuronal, and immunological factors influencing glioblastoma formation, progression, and treatment response,...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded Massachusetts General Hospital a $2.86 million Project Grant under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) on September 19, 2025, with completion targeted for August 31, 2029. The award funds development and validation of CAMPEX (CRISPR-Accelerated Molecular Profiling of Extracellular Vesicles), an innovative diagnostic platform designed to advance cancer detection and monitoring through liquid...
- The National Cancer Institute awarded The General Hospital Corporation (Massachusetts General Hospital) $348,469 under the Cancer Research Manpower program (CFDA 93.398) on September 1, 2026, to support a five-year mentored physician-scientist career development program led by Dr. Christopher Mount, MD PhD. Dr. Mount will use single-cell omics to uncover therapeutic targets, assess tumor dynamics, and define the spatial architecture of cell states to advance CAR-T cell therapies in gliomas, with...
- The National Cancer Institute awarded The General Hospital Corporation, doing business as Massachusetts General Hospital, $161,460 under the Cancer Research Manpower program (CFDA 93.398) on June 1, 2026, to develop quantitative predictive dosimetry for transarterial radioembolization (TARE) in hepatocellular carcinoma treatment. The funded research will design a novel quantitative TARE dosimetry framework capable of predicting realistic yttrium-90 dose distributions to tumor tissue while...
- The National Cancer Institute awarded the University of Massachusetts Medical School $167,500 on May 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to develop and apply a novel sequencing method for mapping 3-methylcytidine (M3C) modifications in messenger RNA at single-nucleotide resolution. The award funds development of HARP-seq, a highly sensitive technique integrating chemical labeling, enrichment strategies, high-throughput sequencing, and bioinformatics to characterize...
- The National Cancer Institute awarded the President and Fellows of Harvard College $604,102 on May 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop bioprinted three-dimensional vascular cancer models that enable study of T cell trafficking, dendritic cell engagement, and tumor cell killing within human and murine tumor microenvironments. The recipient will use microporous embedded printing to fabricate in vitro models incorporating vascular conduits for...